CD8A and metabolic dysfunction-associated steatohepatitis: In addition, CD8+ T cells and anti-PD1 immunotherapy increased NASH-associated HCC, but the outcome was reversed when tumor necrosis factor alpha (TNF-a) was blocked (Pfister et al., 2021).